MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » ACC ’18 Roundup: Abbott releases long-term HeartMate 3 data

ACC ’18 Roundup: Abbott releases long-term HeartMate 3 data

By

ACC '18Abbott (NYSE:ABT) touted two-year data yesterday from its trial designed to compare the company’s HeartMate 3 left ventricular assist device to its HeartMate 2 device in patients with advanced heart failure.

Data from the study were published in The New England Journal of Medicine and presented at the American College of Cardiology’s 67th Annual Scientific Session.

More than 1,000 patients participated in the study. Researchers assessed the trial’s participants for a short-term endpoint of six months and long-term endpoint of two years.

The two-year cohort met its primary endpoint, achieving 77.9% event-free survival – topping the 56.4% rate seen in patients treated with the HeartMate II LVAD.

Patients treated with the HeartMate 3 device had a survival rate of 82.8% after two years, compared to 76.2% for the HeartMate II group. Abbott also reported that low pump thrombosis rates remained low at 1.2% for the HeartMate 3 group, with no reoperations or pump replacements needed at two years.

Finally, the stroke rate in the HeartMate 2 group was 19% compared to just 10% for the patients treated with HeartMate 3.

“The long-term data for the pivotal Momentum 3 trial demonstrate overall survival of 83% at 2-years and marked improvement in clinical outcomes for our patients suffering with advanced heart failure,” Dr. Mandeep Mehra, medical director of Brigham and Women’s Hospital Heart and Vascular Center, said in prepared remarks. “We have seen greater pump durability—mostly driven by an absence of confirmed pump thrombosis—as well as a significantly lowered stroke rate without an increase in other adverse events.”

“As the leader in LVAD therapy, our goal is to provide patients with life-changing health technology that minimizes risk and offers them an enhanced quality of life. Data from the Momentum 3 study show Abbott’s significant progress in LVAD innovation and how it’s improving patient health outcomes,” Dr. John O’Connell, medical director for Abbott’s mechanical circulatory support business, added.

Abbott’s HeartMate 3 LVAD has CE Mark clearance in the E.U. and is approved by the FDA in the U.S. for short-term use. The company plans to use data from its Momentum 3 trial to support an regulatory bid for a long-term indication for HeartMate 3 in the U.S.

NEXT: Philips touts NEJM study on iFR v. FFR

In case you missed it

RSS From Medical Design & Outsourcing

  • 5 medtech companies win coveted Tekne awards
    Five medtech companies recently won some of the top technology awards in the state of Minnesota, known as one of three major medical device hubs in the U.S. The companies competed for the Minnesota Technology Association annual Tekne Awards, which included categories ranging from artificial intelligence and machine learning to “technology for good.” “The Tekne… […]
  • Spectrum Plastics acquires PeelMaster Medical
    Spectrum Plastics Group announced that it has closed on the acquisition of PeelMaster Medical Packaging. Based in Niles, Ill., PeelMaster is a full-service converter of sterile flexible packaging to the medical device market. Founded in 1989, PeelMaster produces pouches, header bags and die-cut lids for medical applications. PeelMaster has been an authorized converter of DuPont… […]
  • The best places to work for medtech sales reps
    Teleflex (NYSE:TFX), ConMed (NSDQ:CNMD) and orthopedic fixation company Acumed top the list of best places to work in medtech sales in the coming year, according to a MedReps.com survey of medical sales representatives. The 10th annual MedReps survey polled more than 2,000 medical sales professionals in October 2020 to get a better understanding of what employees look for… […]
  • Researchers tout probes for validating rapid COVID-19 tests
    Nanoengineers at the University of California San Diego have developed probes that they say could make validating rapid, point-of-care COVID-19 tests easier. The probes, called “positive controls,” are made from virus-like particles and are stable and easy to manufacture, according to a news release. The researchers at UCSD believe the positive controls can improve the… […]
  • How ResMed is advancing sleep and respiratory care
    The COVID-19 pandemic’s propulsion of widespread telehealth adoption has ResMed (NYSE:RMD) eyeing remote technologies for the next phase of its sleep and respiratory businesses. The president of that business for the San Diego-based company, Jim Hollingshead, told Medical Design & Outsourcing in a recent interview that the future lies with remote care and digital health offerings. “Right… […]
  • Stricter Documentation Requirements Pose New Challenges for Medical Device Manufacturers
    By Maurizio Lauria, Brand Manager, STEUTE Meditech Inc. New European guidelines and standards have greatly increased the testing and documentation required in order to introduce a new medical device, making the process even more complex and time-consuming for medical device manufacturers. Additionally, these standards apply not only to the device itself but the user interface,… […]
  • Tips to help bring your medical device from mind to market
    By Bret Ludwig, Ph.D. Senior Product Development Specialist, 3M Medical Materials & Technologies Great medical devices start with an idea—a spark. And from there, it might move to the back of a napkin or a notepad. But as development continues, the process can get trickier and more complex. In fact, turning an idea into a… […]
  • FDA allows dry heat treatment for single-user mask reuse
    The FDA has announced that it will allow the use of dry heat to lower the bioburden on masks used by healthcare workers treating COVID-19 patients. While not authorizing equipment made by a particular company, guidance released last week said healthcare providers may use dry heat to reprocess NIOSH-approved filtering facepiece respirators, such as N95s,… […]
  • Mass General researchers tout low-cost, portable brain imaging scanner
    Researchers at Massachusetts General Hospital are touting a low-cost, portable “head only” MRI scanner that could be used in multiple settings. As opposed to standard costly, immobile MRI scanners that require special infrastructure, the MGH researchers developed a low-cost, compact, portable and low-power scanner that could be mounted in an ambulance, wheeled into a patient’s… […]
  • HHS confirms involvement in presidential transition process
    U.S. Health and Human Services Dept. Secretary Alex Azar confirmed that HHS is working with president-elect Joe Biden on a presidential transition. Speaking during a press briefing, Azar said HHS is in contact with the transition team after the General Services Administration formally recognized Biden as the president-elect, having previously sidestepped questions regarding the potential… […]
  • Swiss scientists make ‘micromachines’ for self-deploying stents and more
    Researchers in Zurich reported today that they have invented a manufacturing technique to build “micromachines” out of metal and plastic in which these two materials are interlocked as closely as links in a chain. These robots are so tiny that they can maneuver through blood vessels and deliver medications to certain points in the body… […]